MX2020011991A - Inhibidores de la oncoproteina ras, metodos de produccion y metodos de uso de los mismos. - Google Patents
Inhibidores de la oncoproteina ras, metodos de produccion y metodos de uso de los mismos.Info
- Publication number
- MX2020011991A MX2020011991A MX2020011991A MX2020011991A MX2020011991A MX 2020011991 A MX2020011991 A MX 2020011991A MX 2020011991 A MX2020011991 A MX 2020011991A MX 2020011991 A MX2020011991 A MX 2020011991A MX 2020011991 A MX2020011991 A MX 2020011991A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- ras oncoprotein
- ras
- inhibitors
- production
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/66—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862669926P | 2018-05-10 | 2018-05-10 | |
| PCT/US2019/031885 WO2019217933A1 (en) | 2018-05-10 | 2019-05-10 | Inhibitors of the ras oncoprotein, methods of making and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020011991A true MX2020011991A (es) | 2021-04-12 |
Family
ID=68467113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011991A MX2020011991A (es) | 2018-05-10 | 2019-05-10 | Inhibidores de la oncoproteina ras, metodos de produccion y metodos de uso de los mismos. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12582660B2 (https=) |
| EP (1) | EP3790541B1 (https=) |
| JP (2) | JP2021528368A (https=) |
| KR (1) | KR20210009331A (https=) |
| CN (1) | CN112312901B (https=) |
| AU (1) | AU2019265011B2 (https=) |
| CA (1) | CA3099148A1 (https=) |
| IL (1) | IL278596B2 (https=) |
| MX (1) | MX2020011991A (https=) |
| WO (1) | WO2019217933A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112312901B (zh) | 2018-05-10 | 2024-05-14 | 路易斯维尔大学研究基金会有限公司 | Ras癌蛋白抑制剂及其制备方法和使用方法 |
| IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
| MX2023002248A (es) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60233051A (ja) | 1984-05-04 | 1985-11-19 | Daicel Chem Ind Ltd | ２−クロル−５−ニトロベンゼンスルホンアミドの製造方法 |
| US4944796A (en) * | 1988-11-14 | 1990-07-31 | Ici Americas Inc. | Certain 2-(disubstituted amino) acetanilide herbicides |
| CN1145608C (zh) * | 1998-06-09 | 2004-04-14 | 诺特兰药品有限公司 | 作为镇咳剂的季铵化合物 |
| US20080139534A1 (en) | 2006-12-07 | 2008-06-12 | Xavier University Of Louisiana | Bisbenzamidines and bisbenzamidoximes for the treatment of human African trypanosomiasis |
| US7951806B2 (en) * | 2007-07-25 | 2011-05-31 | Renascience Co., Ltd. | Plasminogen activator inhibitor-1 inhibitor |
| FR2925495B1 (fr) * | 2007-12-21 | 2010-09-10 | Pf Medicament | Derives dimeriques d'artemisinine et application en therapie anticancereuse |
| GB0808282D0 (en) | 2008-05-07 | 2008-06-11 | Medical Res Council | Compounds for use in stabilizing p53 mutants |
| CN101919842A (zh) | 2009-06-11 | 2010-12-22 | 复旦大学 | 一种苯丙噻吩衍生物在制备抗肿瘤药物中的应用 |
| US8557980B2 (en) | 2010-02-18 | 2013-10-15 | The Board Of Trustees Of The University Of Illinois | Methods for forming protected organoboronic acids |
| AU2011239537A1 (en) * | 2010-04-16 | 2012-11-15 | Curis, Inc. | Treatment of cancers having K-ras mutations |
| KR20120048223A (ko) | 2010-11-05 | 2012-05-15 | 주식회사 이큐스앤자루 | 2-페닐-4-[3-(치환된-설포닐)아닐리노]퀴나졸린 유도체, 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 ｃ형 간염의 예방 또는 치료용 약학적 조성물 |
| GB201020397D0 (en) | 2010-12-02 | 2011-01-12 | Univ Nottingham | Compounds |
| EP2759533B1 (en) | 2011-09-22 | 2017-08-02 | Takeda Pharmaceutical Company Limited | Condensed heterocyclic compound |
| WO2014037726A1 (en) * | 2012-09-06 | 2014-03-13 | Verona Pharma Plc | Liquid pharmaceutical compositions |
| ES2491390B1 (es) * | 2013-02-04 | 2015-06-22 | Universidad Complutense De Madrid | Nuevos inhibidores de la enzima isoprenilcisteina carboximetiltransferasa (icmt) |
| EP2984088B1 (en) | 2013-04-12 | 2019-03-20 | Asana BioSciences, LLC | Quinazolines and azaquinazolines as dual inhibitors of ras/raf/mek/erk and pi3k/akt/pten/mtor pathways |
| US9181288B2 (en) | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| US20160168108A1 (en) * | 2014-12-16 | 2016-06-16 | Adt Pharmaceuticals, Inc. | Method of treating or preventing ras-mediated diseases |
| CA3017211A1 (en) | 2016-03-16 | 2017-09-21 | Endocyte, Inc. | Carbonic anhydrase ix inhibitor conjugates and uses thereof |
| CN112312901B (zh) | 2018-05-10 | 2024-05-14 | 路易斯维尔大学研究基金会有限公司 | Ras癌蛋白抑制剂及其制备方法和使用方法 |
-
2019
- 2019-05-10 CN CN201980038063.7A patent/CN112312901B/zh active Active
- 2019-05-10 US US17/053,057 patent/US12582660B2/en active Active
- 2019-05-10 MX MX2020011991A patent/MX2020011991A/es unknown
- 2019-05-10 IL IL278596A patent/IL278596B2/en unknown
- 2019-05-10 AU AU2019265011A patent/AU2019265011B2/en not_active Expired - Fee Related
- 2019-05-10 KR KR1020207035159A patent/KR20210009331A/ko not_active Ceased
- 2019-05-10 EP EP19800358.4A patent/EP3790541B1/en active Active
- 2019-05-10 WO PCT/US2019/031885 patent/WO2019217933A1/en not_active Ceased
- 2019-05-10 CA CA3099148A patent/CA3099148A1/en active Pending
- 2019-05-10 JP JP2020562120A patent/JP2021528368A/ja active Pending
-
2024
- 2024-02-19 JP JP2024022691A patent/JP2024056937A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL278596B2 (en) | 2025-05-01 |
| AU2019265011A1 (en) | 2020-11-26 |
| CA3099148A1 (en) | 2019-11-14 |
| KR20210009331A (ko) | 2021-01-26 |
| AU2019265011B2 (en) | 2025-01-30 |
| IL278596B1 (en) | 2025-01-01 |
| JP2021528368A (ja) | 2021-10-21 |
| CN112312901B (zh) | 2024-05-14 |
| EP3790541B1 (en) | 2024-12-04 |
| IL278596A (https=) | 2020-12-31 |
| WO2019217933A1 (en) | 2019-11-14 |
| EP3790541A4 (en) | 2022-02-16 |
| US12582660B2 (en) | 2026-03-24 |
| EP3790541A1 (en) | 2021-03-17 |
| WO2019217933A8 (en) | 2021-02-11 |
| JP2024056937A (ja) | 2024-04-23 |
| US20210137939A1 (en) | 2021-05-13 |
| CN112312901A (zh) | 2021-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR122783A2 (es) | Inhibidores de kras g12c y métodos para su uso | |
| CY1124046T1 (el) | Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος | |
| MX2020001757A (es) | Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. | |
| ECSP18094983A (es) | Derivados de pirazol como inhibidores de la calicreína plasmática | |
| EA201891049A1 (ru) | Изоиндолиновые, азаизоиндолиновые, дигидроинденоновые и дигидроазаинденоновые ингибиторы mnk1 и mnk2 | |
| CO2021005532A2 (es) | Derivados de quinolina como inhibidores de la integrina alfa4beta7 | |
| EA201890594A1 (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| GT201600123A (es) | Inhibidores de syk | |
| UY35617A (es) | Inhibidores de la fosfatidilinositol 3-quinasa | |
| EA201792259A1 (ru) | Бензимидазольные и имидазопиридиновые карбоксимидамидные соединения | |
| ECSP17026210A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos | |
| EA201790317A1 (ru) | Ингибиторы smyd | |
| MX2016014253A (es) | Inhibidores de desmetilasa-1 especifica de lisina. | |
| EA201890308A1 (ru) | Замещенные азасоединения как ингибиторы irak-4 | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| EA201792116A1 (ru) | Ингибитор янус-киназы | |
| EA201692487A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| UY35242A (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| UY36207A (es) | Inhibidores de la syk | |
| EA201692266A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| AR103680A1 (es) | Inhibidores selectivos de bace1 | |
| BR112018068412A2 (pt) | composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral | |
| EA201692265A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы |